SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Fridays selloff and the October 19 anniversary of 1987s Black Monday fueled crash calls, but traders debated the risk after futures turned higher: many saw the warnings as crowded bearish positioning, while others called the bounce a bull trap amid AI and tech weakness and a busy earnings week.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Q3 earnings are the central focus, with traders debating whether margins and cash flow can hold and whether managements robotaxi and AI plans justify confidence despite strong deliveries. The Roadster demo drew both praise and skepticism, but many traders say it does little to resolve concerns ahead of the results.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await confirmation of the 80th death event in its blinded Phase 3 REGAL trial of GPS in AML; the last confirmed count was 78. Bulls view the extended wait as a possible sign of longer survival, while bears question the delay and trial design, and the recent selloff has intensified debate over the companys silence and volatile trading.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and semiconductor-led selloff, alongside worries about AI spending and debt, has traders debating whether QQQ faces deeper losses or an oversold rebound. Black Monday crash calls are widely disputed, with bulls pointing to a futures bounce and bears warning it could be a bull trap as major tech earnings approach.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins choppy trading around a closely watched support zone, including reports of leveraged long liquidations and difficulty reclaiming resistance, is driving discussion. Bulls see consolidation and a possible short squeeze, while bears warn of further downside, citing weak ETF flows and broader risk-off concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trumps waiver of Russia-related sanctions and tariffs dominates discussion, with traders criticizing the move as favorable to Putin and questioning its political and market implications. Some defend it as a way to ease energy costs, while bearish comments also point to DJTs recent lows and concerns about the companys business performance.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

EROCs large Anthropic order and Meta-linked data-center power project are driving discussion of its growing backlog and role in supplying natural-gas microgrids amid grid constraints; bullish traders are focused on whether upcoming results show the contracts converting into revenue. Skeptics point to execution and CEO concerns, while others debate the stocks sharp swings and short interest.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO results for Iovances lifileucel-plus-Keytruda frontline melanoma study are driving attention, with traders highlighting durable responses and deeper complete responses. Some see the update as confirmation of promise, while others argue it largely reiterates earlier, small-cohort data and say the Phase 3 trial must validate it; several also attribute the share-price weakness to a broader biotech selloff.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention as small caps sell off amid hotter-than-expected inflation data and worries that the Fed may keep rates higher or hike again, pressuring companies sensitive to borrowing costs. Traders are debating whether oversold conditions and support levels could spark a bounce, while others cite technical breakdowns and put buying as signs of continued weakness.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

A Cedar Point coaster was shut down after a bracket reportedly came loose during a ride, renewing safety and maintenance concerns after earlier fatal-accident discussion around Six Flags. Traders are split between viewing the incidents as a temporary reputational setback and seeing them as compounding the companys existing debt and financial pressures.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO) SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...

Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...

Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...

Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...

Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research

Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average   - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy 

Equity

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 


Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...

Fortress Biotech reported Q1 2026 consolidated net income of $108.4 million, or $2.82 per diluted share, driven by a $205 million priority review voucher sale, compared to a prior year loss.

Fortress Biotech faces risks from failed clinical trial primary endpoints, significant derivative liability charges, and the inherent uncertainty regarding the realization of future milestone and royalty-based revenue streams for Fortress.

Fortress Biotech achieved significant liquidity through the $205 million priority review voucher sale, expanded commercial payer access for Emrosi, and improved the company balance sheet through material debt reduction.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.87
Prev Close	$1.91
Open	$1.92
Dividend Yield	0.00%
50-Day Moving Average	$2.48
Beta	0.86
Avg. Volume	270,605.93
PE Ratio	0.70

52-Week High	$4.53
52-Week Low	$1.84
Market Capitalization	$62.37M
EPS (Annual)	-$0.0674
Price to Book	0.38
Revenue Per Employee	$811,051.28

Feed

News

Sentiment

Earnings

Fundamentals

Info

FBIO Fundamentals